Insmed Incorporated (NASDAQ:INSM) CEO Sells $1,444,312.50 in Stock

Insmed Incorporated (NASDAQ:INSM) CEO William Lewis sold 18,750 shares of the firm’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $77.03, for a total value of $1,444,312.50. Following the completion of the sale, the chief executive officer now directly owns 334,186 shares of the company’s stock, valued at approximately $25,742,347.58. This trade represents a 5.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.

William Lewis also recently made the following trade(s):

• On Monday, March 3rd, William Lewis sold 18,750 shares of Insmed stock. The stock was sold at an average price of $77.79, for a total transaction of $1,458,562.50.
• On Tuesday, February 18th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $81.03, for a total transaction of $1,519,312.50.
• On Thursday, February 6th, William Lewis sold 79,350 shares of Insmed stock. The shares were sold at an average price of $80.90, for a total value of $6,419,415.00.
• On Monday, February 3rd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $77.94, for a total transaction of $1,461,375.00.
• On Wednesday, January 15th, William Lewis sold 31,805 shares of Insmed stock. The stock was sold at an average price of $70.18, for a total value of $2,232,074.90.
• On Friday, January 10th, William Lewis sold 2,978 shares of Insmed stock. The shares were sold at an average price of $63.36, for a total value of $188,686.08.
• On Tuesday, January 7th, William Lewis sold 8,218 shares of Insmed stock. The stock was sold at an average price of $66.02, for a total transaction of $542,552.36.
• On Thursday, January 2nd, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.84, for a total value of $1,309,500.00.
• On Thursday, December 19th, William Lewis sold 18,750 shares of Insmed stock. The shares were sold at an average price of $69.91, for a total value of $1,310,812.50.

Insmed Stock Performance

NASDAQ INSM traded up $1.95 on Wednesday, hitting $78.94. 1,137,784 shares of the stock were exchanged, compared to its average volume of 2,169,416. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The business’s fifty day moving average is $76.61 and its 200 day moving average is $73.70. The company has a market capitalization of $14.29 billion, a PE ratio of -14.12 and a beta of 1.28. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $84.91.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. Insmed had a negative return on equity of 4,773.73% and a negative net margin of 251.24%. Research analysts anticipate that Insmed Incorporated will post -4.56 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the company. Morgan Stanley boosted their price objective on Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research report on Thursday, February 6th. Guggenheim reiterated a “buy” rating and issued a $101.00 target price on shares of Insmed in a report on Tuesday, February 25th. HC Wainwright restated a “buy” rating and set a $90.00 price objective on shares of Insmed in a research report on Friday, February 21st. Stifel Nicolaus cut their price objective on shares of Insmed from $97.00 to $96.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Insmed in a research note on Wednesday, February 19th. One research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Insmed has a consensus rating of “Moderate Buy” and a consensus target price of $93.33.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in INSM. Elequin Capital LP bought a new stake in Insmed during the 4th quarter worth approximately $28,000. Steward Partners Investment Advisory LLC boosted its position in shares of Insmed by 65.2% during the 4th quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 163 shares in the last quarter. V Square Quantitative Management LLC boosted its holdings in shares of Insmed by 60.3% during the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after buying an additional 248 shares in the last quarter. Spire Wealth Management bought a new position in shares of Insmed during the 4th quarter worth about $47,000. Finally, Smartleaf Asset Management LLC boosted its position in shares of Insmed by 98.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 830 shares of the biopharmaceutical company’s stock worth $57,000 after purchasing an additional 411 shares in the last quarter.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.